KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Gross Margin (2016 - 2025)

Boston Scientific's Gross Margin history spans 17 years, with the latest figure at 69.59% for Q4 2025.

  • For Q4 2025, Gross Margin rose 174.0% year-over-year to 69.59%; the TTM value through Dec 2025 reached 69.01%, up 40.0%, while the annual FY2025 figure was 69.01%, 41.0% up from the prior year.
  • Gross Margin for Q4 2025 was 69.59% at Boston Scientific, roughly flat from 69.93% in the prior quarter.
  • Across five years, Gross Margin topped out at 70.63% in Q2 2023 and bottomed at 67.51% in Q1 2021.
  • The 5-year median for Gross Margin is 68.88% (2021), against an average of 68.94%.
  • The largest annual shift saw Gross Margin skyrocketed 878bps in 2021 before it tumbled -152bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 68.92% in 2021, then dropped by 0bps to 68.85% in 2022, then rose by 1bps to 69.23% in 2023, then dropped by -2bps to 67.86% in 2024, then rose by 3bps to 69.59% in 2025.
  • Per Business Quant, the three most recent readings for BSX's Gross Margin are 69.59% (Q4 2025), 69.93% (Q3 2025), and 67.65% (Q2 2025).